Edition:
United Kingdom

BeyondSpring Meets Primary Objective in Phase 2 Portion of Phase 2/3 Trial (Study 105) with Plinabulin


Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Beyondspring Inc ::BEYONDSPRING MEETS PRIMARY OBJECTIVE IN PHASE 2 PORTION OF PHASE 2/3 TRIAL (STUDY 105) WITH PLINABULIN FOR THE PREVENTION OF DOCETAXEL CHEMOTHERAPY-INDUCED NEUTROPENIA (CIN).BEYONDSPRING INC - INTERIM ANTI-CANCER EFFICACY DATA FROM PHASE 3 NSCLC CLINICAL TRIAL IS EXPECTED IN MID-2018. 

Company Quote

16.22
-0.11 -0.67%
9:00pm BST